Galectin Therapeutics (GALT) Q4 2024 Annual Earnings
GALT·Reported March 31, 2025·Before market open
Galectin Therapeutics reported Q4 2024 revenue of $36.0K. Diluted EPS came in at $-0.19, missed the $-0.16 consensus by $0.03.
Revenue
$36.0K
Diluted EPS
$-0.19missed by $0.03
Consensus: $-0.16
Financial Snapshot
Trailing eight quarters through Q4 2024
Q4 2024 Earnings FAQ
Common questions about Galectin Therapeutics's Q4 2024 earnings report.
Galectin Therapeutics (GALT) reported Q4 2024 earnings on March 31, 2025 before market open.
Galectin Therapeutics reported revenue of $36.0K and diluted EPS of $-0.19 for Q4 2024.
EPS missed the consensus estimate of $-0.16 by $0.03.
You can read the 10-K periodic report (0001140361-25-011169) directly on SEC EDGAR. The filing index links above go to sec.gov.